Dr. Kaylen Silverberg is the Medical Director, co-founder, and managing partner of the Texas Fertility Center. He is also a co-founder of Austin IVF, San Antonio IVF, and the Austin Fertility Surgery Center. In 2016, Dr. Silverberg co-founded Ovation Fertility, the nation’s leading network of IVF laboratories. Over the past 7 years, Ovation has successfully completed three private equity sales, partnering with Windrose Health Investors, Morgan Stanley Capital Partners, and Amulet Capital Partners. Most recently, Ovation merged with US Fertility to form the largest fertility platform in the United States. Dr. Silverberg also serves as a Clinical Associate Professor in the Division of Reproductive Endocrinology and Infertility at the Texas A&M University Medical School. He is certified by the American Board of Obstetrics and Gynecology in both OB/GYN and Reproductive Endocrinology/Infertility.In addition to managing his busy private infertility practice, Dr. Silverberg holds many extra-mural appointments. He is the Chairman of the Medical Advisory Board for Americans for IVF, and has twice been a Clinical Director on the Executive Council of the Society of Assisted Reproductive Technology (SART), the organization that oversees all of the IVF programs in the United States. He is a member of the Progyny Medical Advisory Board, and he is also President of the Governing Board of the North Austin Surgery Center.In addition to being cited annually in Best Doctors in America, Texas Super Doctors, US News and World Report Top Doctors, and America’s Top Obstetricians and Gynecologists, Dr. Silverberg is actively involved in clinical infertility research. He holds a patent on the Mannose binding assay, a test of sperm function, and has published over 60 peer-reviewed papers in leading fertility journals as well as over 10 chapters in textbooks of infertility and gynecology.Dr. Silverberg has bachelor degrees in finance and molecular biology, and currently serves as a consultant in the areas of healthcare strategy and policy to several Fortune 500 companies, four United States Congressmen, several private equity and venture capital firms, and numerous pharmaceutical and biotechnology companies.